HONG KONG DRUG LICENSING

Hong Kong Drug Licence FAQs

Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.

Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.

Official information from the Drug Office Official information from the Chinese Medicines Board

找到 50 条结果，第 3／3 页。每页显示 20 条；无需启用 JavaScript。

Thematic illustration for pharmaceutical licensing business queries and document organisation services — Discuss actual operating questions one-to-one to clarify the next decision.

Q41 · 香港的药牌可以转让或许可给第三方使用吗？独立链接

No. Hong Kong pharmacy and poisons licences are non-transferable. A licence is issued to a specific applicant (an individual or company) and is linked to the specific premises, key personnel and Quality Management System submitted with the application. The regulatory authority’s decision is based on an assessment of the overall compliance capability of that specific applicant. Therefore, if a company holding a pharmaceutical licence is acquired by another company, or a pharmacy business is sold to a new operator, the new owner or operator must submit a completely new licence application to the regulatory authority in its own name. It must demonstrate that it can also meet all statutory requirements. The old licence ceases to be valid when the business changes hands. Similarly, a licence holder must not “licence” or “lend” its licence to a third party to operate a medicines business in the third party’s name; this is a serious violation.

📘 Regulatory basis

The non-transferability of licences is a fundamental principle of Hong Kong’s licensing system, reflected in the Pharmacy and Poisons Ordinance and the terms under which relevant licences are issued. Any change in business ownership is regarded as requiring a new licence assessment.

📗 Drew Tang's recommendations

For any M&A or asset sale involving a licensed business, an application for a new licence must be made a condition precedent to completion. The buyer should conduct thorough compliance due diligence and allow sufficient time (usually several months) to complete the new licence application process.

📕 Risk notice

Any attempt to circumvent the principle that a licence is not transferable by using complex corporate structures or nominee agreements may be detected by the regulator and treated as fraud. If discovered, not only will the new business be unable to operate lawfully, but the individuals and companies involved may also be blacklisted.

Q42 · 如果我的产品是一种中西药复方制剂，它将如何被规管？独立链接

Combination products containing both Western and Chinese medicines are subject to very close scrutiny in Hong Kong and are usually classified and regulated as Western medicines. Under the Pharmacy and Poisons Ordinance, any product containing a Western medicine ingredient listed in the Poisons List is classified as a “pharmaceutical product”, whether or not it also contains Chinese medicine ingredients. Such a product must therefore follow the full Western medicine regulatory pathway: it must be registered with the Pharmacy and Poisons Board (PPB) (and obtain an HK-XXXXX number), and its manufacturer, importer and distributor must hold the relevant Western medicine licences, such as a manufacturer’s licence or wholesaler’s licence. In assessing the product, the regulator will evaluate the safety and quality of both its Western and Chinese medicine ingredients. Claiming that a product is “all natural” or “herbal” when it has been found to contain illegally added Western medicine ingredients is an offence that regulators crack down on severely.

📘 Regulatory basis

The definition of “pharmaceutical product” in section 2 of the Pharmacy and Poisons Ordinance is key. Any product containing a regulated Western medicine ingredient falls within the scope of the Ordinance, regardless of the quantity. This takes precedence over the application of the Chinese Medicine Ordinance.

📗 Drew Tang's recommendations

If you plan to develop or import combination products containing both Western and Chinese medicines, you must consider compliance from the research and development stage. We recommend a comprehensive ingredient analysis and legal assessment to determine the regulatory pathway in Hong Kong and devise a registration and market launch strategy accordingly.

📕 Risk notice

Illegally adding western medicines to unapproved proprietary Chinese medicines or health products (such as “paracetamol” for pain relief, “sibutramine” for weight loss or “sildenafil” for sexual enhancement) is extremely dangerous and a serious offence. It poses a direct threat to consumers’ health and may result in the most severe criminal penalties.

Q43 · 香港的药牌制度对“医疗器械”的规管是怎样的？独立链接

At present, regulation of most “medical devices” in Hong Kong is voluntary, but this is changing. The Medical Device Division (MDD) under the Department of Health has established the Medical Device Administrative Control System (MDACS). Under this system, manufacturers and importers may voluntarily apply to have their medical devices listed to demonstrate that they meet basic safety and performance requirements. Devices are classified into four risk classes (I, II, III and IV). However, if a medical device is used in combination with a pharmaceutical product (for example, a pre-filled medicine syringe or a drug-eluting stent), the “drug-device combination product” will generally be regarded as a pharmaceutical product and subject to mandatory regulation under the Pharmacy and Poisons Ordinance. The Hong Kong Government is planning a comprehensive statutory regulatory framework for medical devices, and it is expected that all medical devices will require mandatory registration before they can be marketed in future.

📘 Regulatory basis

At present, the main basis is the administrative guidance issued by the Department of Health’s Medical Device Division: the Medical Device Administrative Control System. The Pharmacy and Poisons Ordinance applies to drug-device combination products. Mandatory legislation is currently being developed.

📗 Drew Tang's recommendations

For medical device manufacturers and distributors, we strongly recommend participating in the current voluntary listing scheme as early as possible. This not only demonstrates your commitment to product quality to customers and the public, but also prepares you for the future introduction of mandatory regulations and gives you a head start.

📕 Risk notice

Do not assume that all medical devices are unregulated. Regulatory requirements may already be very stringent for high-risk devices, implantable devices or devices used in combination with medicines. Detailed classification and regulatory assessment are essential before introducing any new device.

Q44 · 如果我持有的药牌即将到期，续牌的流程是怎样的？独立链接

Renewal of a pharmaceutical licence is an important procedure that must be completed on time to ensure the lawful continuity of your business. Usually, the Drug Office, Department of Health will mail the renewal application form to the registered address on its records about two to three months before your licence expires. You need to complete the form, update basic company information (such as any changes to directors or the Person-in-Charge), and return it by post or submit it in person to the Drug Office before the licence expires, together with a cheque for the specified renewal fee. The Department will review the application. For higher-risk licences, such as wholesaler or manufacturer licences, it may arrange a re-inspection before deciding on renewal. If all documents are complete, the fee has been paid and the company has a good compliance record, renewal will usually proceed smoothly. The new licence will be mailed to you.

📘 Regulatory basis

The validity period and renewal requirements for licences are expressly set out in the Pharmacy and Poisons Regulations. Renewal fees are listed in Schedule 7 to the Regulations.

📗 Drew Tang's recommendations

Be sure to keep the correspondence address registered with the Department of Health up to date so that you do not miss a renewal notice. We recommend setting up an internal licence management calendar and starting renewal preparations at least three months in advance. Do not leave it until the last minute.

📕 Risk notice

Failure to submit a renewal application or pay the fees on time will cause the licence to expire automatically on its expiry date. Any regulated activity carried out after the licence expires constitutes the serious offence of unlicensed operation. Even a delay of only a few days may require a completely new application, making the process much more complicated.

Q45 · What rules apply in Hong Kong to medicines dispensed following telemedicine consultations?Direct link

With the rise of remote consultations, the related issue of dispensing medicines has also attracted considerable attention. Hong Kong law and professional codes emphasise that standards of healthcare and medicines safety must not be lowered, regardless of the consultation format. According to the guidance of the Medical Council of Hong Kong, if a doctor considers it necessary to issue a prescription after a remote consultation, the doctor must ensure that the prescription is appropriate and supported by sufficient clinical grounds. Dispensing must still comply with the Pharmacy and Poisons Ordinance. This means that prescription medicines must be dispensed at a registered pharmacy by a pharmacist or under a pharmacist’s supervision. Doctors may send prescriptions securely by electronic means to the pharmacy designated by the patient, or the clinic may arrange delivery of the medicines to the patient. During delivery, the safety, integrity and privacy of the medicines must be ensured, and there must be a mechanism for verifying the recipient’s identity. The entire process must be clearly documented and traceable.

📘 Regulatory basis

The Hong Kong Medical Council’s Ethical Guidelines on Practice of Telemedicine and relevant announcements by the Pharmacy and Poisons Board provide a framework for dispensing medicines following remote consultations. The core requirement remains compliance with the Pharmacy and Poisons Ordinance provisions on the sale of prescription medicines.

📗 Drew Tang's recommendations

For platforms or clinics providing telemedicine consultations, establishing a compliant, closed-loop medicine delivery arrangement is key to success. We recommend working with a licensed pharmacy or pharmaceutical wholesaler to jointly design a “last-mile” delivery process consistent with the principles of GDP and GSP.

📕 Risk notice

Remote consultations must never be used as a shortcut to over-prescribe or bypass the professional role of a pharmacist. Prescribing high-risk medicines without a doctor having sufficient understanding of the patient, or a platform shipping prescription medicines directly from a warehouse to patients without the involvement of a pharmacy and pharmacist, carries substantial legal and safety risks.

Q46 · 什么是“药物回收”（Drug Recall）？在什么情况下会发生？独立链接

A medicine recall is an action to retrieve one or more batches of medicines already distributed on the market. It is an important measure to protect the public from medicines that may pose a risk. A recall may be initiated voluntarily by a manufacturer or distributor, or carried out compulsorily at the request of the Department of Health. Recalls may be triggered by various reasons, most commonly quality issues (such as incorrect ingredient content, impurities or packaging errors), safety issues (such as unexpected serious adverse reactions) or compliance issues (such as incorrect label information or use of unapproved raw materials). Recalls are classified by risk level, from the most urgent Class I recall, requiring retrieval to the patient level, to Class III, requiring retrieval only at the wholesale and retail levels. Licensed wholesalers and manufacturers must establish an effective recall procedure to ensure that, when needed, the distribution of affected medicines can be traced quickly and accurately and downstream customers notified.

📘 Regulatory basis

Both the Good Distribution Practice (GDP) for Pharmaceutical Products and the Good Manufacturing Practice (GMP) for Medicinal Products require licensees to establish written recall procedures and conduct mock recalls regularly to test their effectiveness.

📗 Drew Tang's recommendations

An effective batch tracking system is key to a successful recall. We recommend that clients’ inventory management systems record every goods receipt and dispatch by batch number. The ability to generate an accurate distribution list quickly during a recall is an important measure of your management capability in the regulator’s eyes.

📕 Risk notice

Delaying the reporting of a quality issue requiring recall, or acting slowly and failing to provide transparent information during a recall, will seriously undermine the trust of regulators and the public. The ability to handle a recall is a litmus test of whether a pharmaceutical company is responsible.

Q47 · 香港对传统草本药物（Traditional Herbal Medicines）的规管是怎样的？独立链接

Hong Kong's regulation of traditional herbal medicines depends mainly on their source and category. If a herbal medicine falls within the categories of “Chinese herbal medicine” or “proprietary Chinese medicine”, it is subject to comprehensive regulation under the Chinese Medicine Ordinance (Cap. 549). The trader must apply for a Chinese medicine trader licence, and the product (if it is a proprietary Chinese medicine) must also be registered. However, the legal status of “traditional herbal medicines” outside the Chinese medicine system (for example, Western herbal remedies such as St John's wort and echinacea) is less clear. They are generally regulated as ordinary foods or health products, provided they contain no Western medicine ingredients controlled under the Pharmacy and Poisons Ordinance and their claims do not relate to the treatment or prevention of disease. The Department of Health nevertheless monitors these products closely and may investigate if they are found to contain harmful substances or make false medical claims.

📘 Regulatory basis

The Chinese Medicine Ordinance is the principal legislation regulating Chinese medicines. For herbal medicines that are not Chinese medicines, the key considerations are whether they fall within the definition of “pharmaceutical product” under the Pharmacy and Poisons Ordinance, or the food safety provisions of the Public Health and Municipal Services Ordinance.

📗 Drew Tang's recommendations

For companies dealing in various herbal products, it is crucial to clearly determine the legal status of each product. We recommend creating a product file documenting its source, ingredients, traditional uses and all marketing materials, and conducting a compliance risk assessment for each product.

📕 Risk notice

“Natural” does not mean “risk-free”. Many natural herbs contain chemical constituents that are pharmacologically active or even toxic. Selling products containing harmful herbal ingredients as food, or illegally adding Western medicines to herbal products, may result in serious legal consequences.

Q48 · If I only provide warehousing or logistics services to pharmaceutical manufacturers, do I need to apply for a pharmaceutical licence?Direct link

Yes, it is highly likely to be required. Under Hong Kong's GDP requirements, a third-party logistics provider (3PL) that provides medicine storage and transport services must apply for a Wholesale Dealer Licence if its services form part of the medicine distribution chain. Merely providing a “warehouse” or “delivery vehicle” is not sufficient; you must establish a complete Quality Management System (QMS) that complies with GDP requirements. This includes appointing a qualified responsible person, qualifying your storage facilities and cold-chain vehicles, establishing Standard Operating Procedures (SOPs) for receiving, storage, picking, packing and transport of medicines, and having contingency plans for handling deviations and emergencies. The Department of Health considers the quality and safety of medicines to be critical at every stage of the supply chain. Therefore, even if you do not own the medicines, you assume responsibility for safeguarding their quality if you physically handle and store them, and are subject to regulation.

📘 Regulatory basis

The Department of Health’s Good Distribution Practice (GDP) for Pharmaceutical Products clearly states that it applies to all parties involved in pharmaceutical wholesale and distribution activities, including outsourced service providers. This means that third-party logistics companies also need to be licensed.

📗 Drew Tang's recommendations

For logistics companies, obtaining a pharmaceutical wholesaler licence is an important strategic upgrade that allows entry into a professional service sector with high barriers to entry and high added value. RGYS has extensive experience and can guide logistics companies in establishing GDP-compliant quality systems. RGYS may assist with document preparation and project coordination within the written scope of services; personnel qualifications, statutory roles and professional judgments are to be verified and assumed by the respective responsible parties, and approval is decided independently by the competent authority.

📕 Risk notice

A pharmaceutical manufacturer that outsources storage or logistics to an unlicensed third-party company is committing a serious breach. As a manufacturer, you are responsible for ensuring that all outsourced service providers are properly qualified. A thorough compliance audit is essential before selecting a logistics partner.

Q49 · 香港的药剂制品注册，是否接受中国内地药监局（NMPA）的审批结果？独立链接

At present, Hong Kong’s pharmaceutical product registration system simplifies procedures mainly by recognising approval decisions made by the regulatory authorities of certain designated “reference countries”. These include the United States, the United Kingdom, EU Member States, Australia, Canada and Japan. If a medicine has obtained marketing authorisation from at least two authorities in these countries, its application for registration in Hong Kong may benefit from a degree of simplification. However, to date, China’s National Medical Products Administration (NMPA) has not been formally designated as a “reference authority” for Hong Kong medicine registration. This means that even if a medicine has been approved by the NMPA for marketing in mainland China, a full set of technical documents must still be submitted for a comprehensive assessment by the Department of Health when applying for registration in Hong Kong; the simplified procedure is not available. However, as integration within the Greater Bay Area deepens, communication and mutual recognition between the regulatory authorities on both sides are strengthening, and policy may develop in future.

📘 Regulatory basis

The annex to the Department of Health’s Guidelines on Registration of Pharmaceutical Products/Substances lists in detail the “reference countries” accepted for the simplified registration procedure.

📗 Drew Tang's recommendations

For pharmaceutical companies seeking to bring high-quality medicines already marketed in Mainland China to Hong Kong, although the simplified route is unavailable, a well-prepared, high-quality registration dossier remains key to success. We can help you organise, translate and supplement NMPA submission materials in accordance with Hong Kong requirements to meet local assessment standards.

📕 Risk notice

Do not assume that a medicine approved in the Mainland can readily be marketed in Hong Kong. The review standards and areas of focus may differ between the two jurisdictions. A detailed gap analysis is essential before starting a Hong Kong registration project.

Q50 · 香港药牌制度的未来发展趋势是怎样的？独立链接

Hong Kong’s pharmaceutical licensing system is moving towards greater scientific rigour, international alignment and comprehensive coverage. Key future trends include the following. First, risk-based regulation will be further strengthened, with regulatory resources increasingly focused on high-risk products and activities. Second, alignment with international standards will deepen. For example, internationally accepted standards will be adopted comprehensively in areas such as medical devices and clinical trials. Third, the application and regulation of new technologies will become a focus. Regulatory frameworks for advanced therapy products (ATPs), such as cell and gene therapies, are being developed, while clearer guidance is also expected on telemedicine and the use of artificial intelligence in the pharmaceutical sector. Fourth, regulatory coordination and interoperability for medicines and medical devices within the Greater Bay Area will remain a long-term trend, with policies facilitating access for Hong Kong and Macao residents potentially being expanded. For the industry, this means the need for continuous learning and ongoing improvements in compliance to adapt to an increasingly stringent and complex regulatory environment, while also creating opportunities to access broader markets.

📘 Regulatory basis

Government policy addresses, Legislative Council discussion papers, and the strategic plans of the Department of Health and the Hospital Authority all reveal the direction of future pharmaceutical regulatory policy.

📗 Drew Tang's recommendations

As an industry participant, you should embrace change proactively and with a forward-looking attitude. Investing in a Quality Management System, staff training and new technologies is not only about meeting immediate compliance requirements, but also about maintaining a leading position in future competition. Rengangyongsheng (Hong Kong) Limited will work with you to anticipate opportunities and shape the future.

📕 Risk notice

Clinging to old practices and ideas while ignoring developments in regulations and technology is one of the greatest risks to a business. In the rapidly changing pharmaceutical and healthcare sector, businesses that fail to keep pace will ultimately be left behind by the market and regulations.

Hong Kong Drug Licence FAQs

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang